A benefit study of the Gardasil 9 NIP is also forthcoming

Due to the influence of Yoon Seok-yeol's presidential campaign pledge

Herpes zoster vaccine NIP cost-benefit study notice

The KDCA is ordering an additional policy research service to apply the National Vaccination Support Project (NIP) of the 'HPV 9-valent vaccine' to female adolescents and male adolescents over 12 years of age.

 

As the result of the HPV 9 commissioned by KDCA to NECA earlier was found to be low in cost-effectiveness in vaccine research, it is in effect a follow-up study.

 

In addition, the KDCA plans to conduct a cost-effectiveness study when applying NIP to the shingles vaccine.

 

On the 8th, KDCA Medical Safety and Prevention Director Lim Eul-ki made this statement at a meeting with the Professional Reporters Association.

 

Director Lim Eul-ki explained, "The additional study on the cost-effectiveness of the male HPV 9 vaccine will be conducted as quickly as possible and an order will be placed in May." The policy of free vaccination of Gardasil 9, a vaccine against HPV 9, to female and male adolescents was a pledge of President Seok-Yeol Yoon during the presidential election.

 

To this end, the KDCA commissioned NECA to conduct a cost-effectiveness study, but it was concluded that it was not cost-effective in all analysis scenarios.

 

Specifically, the research team analyzed the economic effects of three scenarios: ▲ 12-year-old girl 9-valent conversion, ▲ 12-year-old male and female 9-valent vaccination, ▲ and 12-year-old male HPV vaccine NIP subject to NIP However, as a result, the cost-benefit ratio was not significant in all scenarios.

 

Accordingly, KDCA decided to conduct a cost-benefit analysis again through additional research.

 

The subject of the follow-up study was decided to be kept private for the time being to maintain research fairness.

 

Regarding the background of the additional research, Director Lim Eul-ki explained, "There were many experts' opinions that the research design of the research service conducted by NECA was carried out excessively conservatively." Director Lim explained, "For example, we underestimated the diseases that occur in men during the HPV vaccine effect." Director Lim said, "There was an expert opinion that the effect on side diseases such as head and neck cancer was also underestimated.

 

In follow-up studies, we plan to actively reflect this aspect." Director Lim added, “In particular, it should have been studied compared to female non-vaccinated people, but there was also an evaluation that the sensitivity was lowered because of the study compared to female non-vaccinated people.” Director Lim added, "In fact, research services have been conducted overseas as well, and additional research is being ordered in Korea under the same conditions." The KDCA will also embark on a NIP cost-benefit study of the shingles vaccine.

 

The research will also be ordered in May.

 

Director Lim said, "It would be nice if NIP was implemented for the shingles vaccine, but it was difficult to proceed due to budget limitations.

 

This research service will include the recently released Shingrix vaccine." Lim said, "Unlike HPV vaccine research, the period required for research on shingles is planned to be about one year with time to spare."